| __timestamp | Neurocrine Biosciences, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 31354781 |
| Thursday, January 1, 2015 | 81491000 | 43445817 |
| Friday, January 1, 2016 | 94291000 | 66489820 |
| Sunday, January 1, 2017 | 121827000 | 96886134 |
| Monday, January 1, 2018 | 160524000 | 153793000 |
| Tuesday, January 1, 2019 | 200000000 | 148369000 |
| Wednesday, January 1, 2020 | 275000000 | 151934000 |
| Friday, January 1, 2021 | 328100000 | 198532000 |
| Saturday, January 1, 2022 | 463800000 | 112128000 |
| Sunday, January 1, 2023 | 565000000 | 76192000 |
| Monday, January 1, 2024 | 731100000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and TG Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Neurocrine Biosciences increased its R&D spending by over 1,100%, peaking at $565 million in 2023. This substantial growth underscores their aggressive pursuit of new therapies and technologies. In contrast, TG Therapeutics, Inc. showed a more modest increase of approximately 143% over the same period, with a peak expenditure of $199 million in 2021. This divergence highlights different strategic priorities, with Neurocrine focusing heavily on innovation, while TG Therapeutics maintains a more conservative approach. As the biotech landscape evolves, these investment strategies will likely shape the future trajectories of these companies.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Expenses Breakdown: Grifols, S.A. vs TG Therapeutics, Inc.
R&D Insights: How TG Therapeutics, Inc. and Xenon Pharmaceuticals Inc. Allocate Funds